Top

Cellular Oncology

Published in:

01-04-2018 | Original Paper

Synergistic anticancer effect of panobinostat and topoisomerase inhibitors through ROS generation and intrinsic apoptotic pathway induction in cervical cancer cells

Authors: Lubna Wasim, Madhu Chopra

Published in: Cellular Oncology | Issue 2/2018

Abstract

Purpose

Various combinations of drugs may be effective in the treatment of different types of cancer. Previously, we have shown that combinations of the histone deacetylase inhibitor panobinostat and the topoisomerase inhibitors topotecan or etoposide act synergistically, but the underlying mode of action has remained unknown. Here, we aimed at uncovering the mechanisms underlying this synergism.

Methods

The effects of (combinations of) panobinostat and topotecan or etoposide on cervical cancer-derived HeLa and SiHa cells were assessed using morphological evaluations, scratch wound healing assays, cell cycle analyses, AO/EB staining assays, Annexin V/PI staining assays, reactive oxygen species (ROS) and mitochondrial membrane potential measurements and Western blotting.

Results

We found that combinations of panobinostat and the topoisomerase inhibitors topotecan or etoposide synergistically enhanced the induction of apoptosis in both HeLa and SiHa cells. This enhanced apoptosis induction was found to be mediated through increased ROS production and induction of the mitochondrial apoptotic pathway. We also found that the combination treatment resulted in inhibition of the PI3K/AKT and NF-κB pro-survival pathways and in activation of the ERK pathway, which is associated with intrinsic apoptosis.

Conclusions

From our data we conclude that combinations of panobinostat and the topoisomerase inhibitors topotecan or etoposide provoke strong cell death responses in cervical cancer-derived cells via induction of the intrinsic apoptotic pathway. Since this drug combination may potentially be effective in the treatment of cervical cancer, further preclinical investigations are warranted.

Available only for authorised users

Y. Sun, Z. Sheng, C. Ma, K. Tang, R. Zhu, Z. Wu, R. Shen, J. Feng, D. Wu, D. Huang, D. Huang, J. Fei, Q. Liu, Z. Cao, Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer. Nat Commun 6, 8481 (2015). https://doi.org/10.1038/ncomms9481 CrossRefPubMedCentralPubMed

S. Grant, Is the focus moving toward a combination of targeted drugs? Best Pract Res Clin Haematol 21, 629–637 (2008). https://doi.org/10.1016/j.beha.2008.08.003 CrossRefPubMedCentralPubMed

M. Bots, R.W. Johnstone, Rational combinations using HDAC inhibitors. Clin Cancer Res 15, 3970–3977 (2009). https://doi.org/10.1158/1078-0432.CCR-08-2786 CrossRefPubMed

J. Gray, C.L. Cubitt, S. Zhang, A. Chiappori, Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. Cancer Biol. Ther. 13, 614–622 (2012). https://doi.org/10.4161/cbt.19848 CrossRefPubMedCentralPubMed

A. Ferraro, Altered primary chromatin structures and their implications in cancer development. Cell Oncol 39, 195–210 (2016). https://doi.org/10.1007/s13402-016-0276-6 CrossRef

L. Nolan, P.W. Johnson, A. Ganesan, G. Packham, S.J. Crabb, Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? Br J Cancer 99, 689–694 (2008). https://doi.org/10.1038/sj.bjc.6604557 CrossRefPubMedCentralPubMed

M.S. Kim, M. Blake, J.H. Baek, G. Kohlhagen, Y. Pommier, F. Carrier, Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63, 7291–7300 (2003)PubMed

K. Ozaki, F. Kishikawa, M. Tanaka, T. Sakamoto, S. Tanimura, M. Kohno, Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drug. Cancer Sci 99, 376–384 (2008). https://doi.org/10.1111/j.1349-7006.2007.00669.x CrossRefPubMed

L. Wasim, M. Chopra, Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells. Biomed Pharmacother 84, 1393–1405 (2016). https://doi.org/10.1016/j.biopha.2016.10.057 CrossRefPubMed

10.

R.S. Hotchkiss, A. Strasser, J.E. McDunn, P.E. Swanson, Cell Death. N Engl J Med 361, 1570–1583 (2009). https://doi.org/10.1056/NEJMra0901217

11.

J.F. Kerr, C.M. Winterford, B.V. Harmon, Apoptosis. Its significance in cancer and cancer therapy. Cancer 73, 2013–2026 (1994). https://doi.org/10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J CrossRefPubMed

12.

K.T. Thurn, S. Thomas, A. Moore, P.N. Munster, Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 7, 263–283 (2011). https://doi.org/10.2217/fon.11.2 CrossRefPubMedCentralPubMed

13.

O. Martinez-Iglesias, L. Ruiz-Llorente, R. Sanchez-Martinez, L. Garcia, A. Zambrano, A. Aranda, Histone deacetylase inhibitors: Mechanism of action and therapeutic use in cancer. Clin Transl Oncol 10, 395–398 (2008). https://doi.org/10.1007/s12094-008-0221-x CrossRefPubMed

14.

D.R. Budman, A. Calabro, L. Rosen, M. Lesser, Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system. Anti-Cancer Drugs 23, 272–279 (2012). https://doi.org/10.1097/CAD.0b013e32834ebda4 CrossRefPubMedCentralPubMed

15.

Y. Cai, X. Yan, G. Zhang, W. Zhao, S. Jiao, The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC. Oncotarget 6, 18997–19005 (2015). https://doi.org/10.18632/oncotarget.3620 PubMedCentralPubMed

16.

S. Venkannagari, W. Fiskus, K. Peth, P. Atadja, M. Hidalgo, A. Maitra, K.N. Bhalla, Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. Oncotarget 3, 1416–1427 (2012). https://doi.org/10.18632/oncotarget.724 CrossRefPubMedCentralPubMed

17.

G. Wang, H. Edwards, J.T. Caldwell, S.A. Buck, W.Y. Qing, J.W. Taub, Y. Ge, Z. Wang, Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. PLoS One 8, e76662 (2013). https://doi.org/10.1371/journal.pone.0076662 CrossRefPubMedCentralPubMed

18.

F. Bruzzese, M. Rocco, S. Castelli, E. Di Gennaro, A. Desideri, A. Budillon, Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther 8, 3075–3087 (2009). https://doi.org/10.1158/1535-7163.MCT-09-0254 CrossRefPubMed

19.

D. Chen, J. Cao, L. Tian, F. Liu, X. Sheng, Induction of apoptosis by casticin in cervical cancer cells through reactive oxygen species-mediated mitochondrial signaling pathways. Oncol Rep 26, 1287–1294 (2011). https://doi.org/10.3892/or.2011.1367 PubMed

20.

L. Gao, M. Gao, G. Yang, Y. Tao, Y. Kong, R. Yang, X. Meng, G. Ai, R. Wei, H. Wu, X. Wu, J. Shi, Synergistic activity of carfilzomib and Panobinostat in multiple myeloma cells via modulation of ROS generation and ERK1/2. Biomed Res Int 2015, 459052 (2015)PubMedCentralPubMed

21.

O. Sordet, Q.A. Khan, I. Plo, P. Pourquier, Y. Urasaki, A. Yoshida, S. Antony, G. Kohlhagen, E. Solary, M. Saparbaev, J. Laval, Y. Pommier, Apoptotic topoisomerase I-DNA complexes induced by staurosporine-mediated oxygen radicals. J Biol Chem 279, 50499–50504 (2004). https://doi.org/10.1074/jbc.M410277200 CrossRefPubMed

22.

M.D. Brand, C. Affourtit, T.C. Esteves, K. Green, A.J. Lambert, S. Miwa, J.L. Pakay, N. Parker, Mitochondrial superoxide: Production, biological effects, and activation of uncoupling proteins. Free Radic Biol Med 37(6), 755–767 (2004). https://doi.org/10.1016/j.freeradbiomed.2004.05.034 CrossRefPubMed

23.

M. Ott, V. Gogvadze, S. Orrenius, B. Zhivotovsky, Mitochondria, oxidative stress and cell death. Apoptosis 12, 913–922 (2007). https://doi.org/10.1007/s10495-007-0756-2 CrossRefPubMed

24.

J.K. Brunelle, A. Letai, Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 122, 437–441 (2009). https://doi.org/10.1242/jcs.031682 CrossRefPubMedCentralPubMed

25.

B. Leibowitz, J. Yu, Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol Ther 9, 417–422 (2010). https://doi.org/10.4161/cbt.9.6.11392 CrossRefPubMedCentralPubMed

26.

V.J. Bouchard, M. Rouleau, G.G. Poirier, PARP-1, a determinant of cell survival in response to DNA damage. Exp Hematol 31, 446–454 (2003). https://doi.org/10.1016/S0301-472X(03)00083-3 CrossRefPubMed

27.

D.A. Altomare, J.R. Testa, Perturbations of the AKT signaling pathway in human cancer. Oncogene 24, 7455–7464 (2005). https://doi.org/10.1038/sj.onc.1209085 CrossRefPubMed

28.

G. Song, G. Ouyang, S. Bao, The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9, 59–71 (2005). https://doi.org/10.1111/j.1582-4934.2005.tb00337.x CrossRefPubMed

29.

K. Vazquez-Santillan, J. Melendez-Zajgla, L. Jimenez-Hernandez, G. Martinez-Ruiz, V. Maldonado, NF-kappaB signaling in cancer stem cells: A promising therapeutic target? Cell Oncol 38, 327–339 (2015). https://doi.org/10.1007/s13402-015-0236-6 CrossRef

30.

F. Chang, J.T. Lee, P.M. Navolanic, L.S. Steelman, J.G. Shelton, W.L. Blalock, R.A. Franklin, J.A. McCubrey, Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia 17, 590–603 (2003). https://doi.org/10.1038/sj.leu.2402824 CrossRefPubMed

31.

M. Barkett, T.D. Gilmore, Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 18, 6910–6924 (1999). https://doi.org/10.1038/sj.onc.1203238 CrossRefPubMed

32.

C. Bubici, S. Papa, C.G. Pham, F. Zazzeroni, G. Franzoso, The NF-kappaB-mediated control of ROS and JNK signaling. Histol Histopathol 21, 69–80 (2006). https://doi.org/10.14670/HH-21.69 PubMed

33.

C. Yu, B.B. Friday, J.P. Lai, A. McCollum, P. Atadja, L.R. Roberts, A.A. Adjei, Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin Cancer Res 13, 1140–1148 (2007). https://doi.org/10.1158/1078-0432.CCR-06-1751 CrossRefPubMed

34.

S. Cagnol, J.C. Chambard, ERK and cell death: Mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence. FEBS J 277, 2–21 (2010). https://doi.org/10.1111/j.1742-4658.2009.07366.x CrossRefPubMed

35.

Z. Lu, S. Xu, ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life 58, 621–631 (2006). https://doi.org/10.1080/15216540600957438 CrossRefPubMed

36.

J.A. McCubrey, L.S. Steelman, W.H. Chappell, S.L. Abrams, E.W. Wong, F. Chang, B. Lehmann, D.M. Terrian, M. Milella, A. Tafuri, F. Stivala, M. Libra, J. Basecke, C. Evangelisti, A.M. Martelli, R.A. Franklin, Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773, 1263–1284 (2007). https://doi.org/10.1016/j.bbamcr.2006.10.001 CrossRefPubMed

37.

M.J. Chuang, S.T. Wu, S.H. Tang, X.M. Lai, H.C. Lai, K.H. Hsu, K.H. Sun, G.H. Sun, S.Y. Chang, D.S. Yu, P.W. Hsiao, S.M. Huang, T.L. Cha, The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation. PLoS One 8, e73401 (2013). https://doi.org/10.1371/journal.pone.0073401 CrossRefPubMedCentralPubMed

Title: Synergistic anticancer effect of panobinostat and topoisomerase inhibitors through ROS generation and intrinsic apoptotic pathway induction in cervical cancer cells
Authors: Lubna Wasim
Madhu Chopra
Publication date: 01-04-2018
Publisher: Springer Netherlands
Published in: Cellular Oncology / Issue 2/2018
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-017-0366-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

Role of β-catenin in cisplatin resistance, relapse and prognosis of head and neck squamous cell carcinoma

Organ-specific metastasis of breast cancer: molecular and cellular mechanisms underlying lung metastasis

p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors

Amphiregulin regulates proliferation and migration of HER2-positive breast cancer cells

Establishing cut-off points with clinical relevance for bcl-2, cyclin D1, p16, p21, p27, p53, Sox11 and WT1 expression in glioblastoma - a short report

Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer